“Make Way for Ducklings!”

Perhaps you’ve read Robert McCloskey’s timeless classic to a child, or had it read to you years ago. Maybe you’ve even seen Mrs. Mallard and her eight bronze ducklings marching in a row through Boston’s Public Garden. It’s a sweet image of order and calm, yet in the story, keeping those ducklings together amid the city hustle was anything but simple.

In biomanufacturing, getting your own “ducks in a row” can be just as challenging. Coordinating donor tissue sourcing, master and working cell bank production, and analytical method development rarely follows a straight line. [1, 2] Each track has its own pace, its own dependencies, and its own surprises. Even a well-laid plan can turn chaotic without experience guiding it forward. To learn more, “paddle” on by to our latest webinar via cell&gene, “Cell Bank and Scale Up Strategies for MSC and Exosome Manufacturing”. [3]

Weave Workflows Before Waddle

Some common missteps include (1) building too small of a Master Cell Bank (MCB) stock; (2) misfit fill size for process needs of cell banks; (3) inadequate characterization and testing of the MCB; (4) variable potency between R&D and GMP lots or materials that fall short of critical quality attributes (CQAs); (5) fickle manufacturability between R&D materials and the cell  banks for clinical production; and (6), inadequate allowance for up to 2/3 of manufactured cell lot failure—common due to contamination or other reasons. SNAFUs that lead to repeat attempts to manufacture another cell bank mean another heavy cost and time investment or lead to the end of a promising therapy before any clinical readouts are reached. How can a cell therapy developer avoid them?

To understand how to best minimize risk, let’s briefly summarize the approximate costs and timelines of three parallel operations tracks of related to building a cell bank. These include MCB production, Working Cell Bank (WCB) production, and analytical method development (see Figure 1, below).

Figure 1. An intricate staged development with many manufacturing steps happening in parallel. A. MCB process development begins by optimization of starting tissue isolation to MCB production (3-6 months; $200K-$400K), followed by donor tissue sourcing and regulatory and safety testing (1-3 months; $50K-$150K). Next, there is the tech transfer and engineering runs to a CDMO skilled in cell therapy to prepare for GMP MCB manufacturing (2 – 4 months; $200K – $400K). Finally, there is MCB manufacturing and release testing (2-4 months; $250K – $500K), which involves full safety testing, product release documentation, and GMP storage. From here, a stability testing program of the bank is implemented. B. Process development for the WCB begins while the MCB is being manufactured and waiting on release testing (3-6 months; $200K-$400K). The next step is the tech transfer of the WCB process (2-4 months; $100K-$150K), followed by the WCB production and testing for release and stability (2-4 months; $200K-$300K). C. While all the manufacturing prep and activity is occurring, a third track is on the analytical methods development needed to eventually release both the MCB and, additionally, the WCB (pending its satisfactory manufacture). This analytical method development is 3-6 months and costs $100K-$200K. The long-term stability program and regulatory support costs an additional $25K per year.

In the best-case scenario, the end-to-end timeline to complete all combined tracks—beginning with MCB and including WCB, and analytical methods development and qualification—runs 1-2 years and costs $millions. However, an insidious drag on the momentum may include opportunity costs form diluted focus. Attention can be drawn away from developing your drug product’s full manufacturing process, understanding your drug product’s CQAs and analytical needs, generating pre-clinical data, preparing for regulatory approval, and running the rest of the business operation.

Another (Less Muddy) Path?

Is there an alternative? Why not leverage existing expertise and infrastructure rather than rebuild it? RoosterBio’s CliniControl™ working cell banks are fully GMP-compliant “CMOs in a vial,” produced under ISO-certified cleanroom conditions and supported by FDA-referenced Type II Biologics Master Files. Each lot is extensively tested for safety, identity, viability, and biological activity, then released with a detailed Certificate of Analysis and a long-term stability program already in place.

Because the data behind these banks have already been reviewed by regulators, developers can reference the Type II Biologics Master Files directly in their own IND submissions. [4] This removes an entire layer of redundant documentation and sharply reduces CMC-related risk. More importantly, it allows a team’s attention to shift back where it belongs, on the product itself.

Within the same twelve-month window and approximate budget that it would take to merely approach working cell bank release internally from a de novo initiative, programs that partner with RoosterBio can instead be filing their first-in-human applications and manufacturing clinical-grade doses. Time once spent on infrastructure becomes time invested in data generation and proof of concept.

Ready Runway for Roosters

Duck hatchlings can’t fly right away, and neither can cell therapies. Luckily, a strong and growing network of CDMOs is trained to expertly bridge advanced therapeutics that involve cells, synthetic genes, and gene-modified cell products across clinical development’s proverbial “valley of death.” [5, 6, 7, 8] Hand-in-hand with this group, there’s also a special niche of Process Development and Technology Transfer Organization (PD/TTO) allies who can outfit them with GMP-certified raw materials (cells, growth media, and other media) as well as bioprocesses to consistently manufacture final dose vials at right scale.  RoosterBio is one such partner, a catalyst to accelerate time-to-clinic. [9]

In the right environment, webbed anatine feet (ducklings) can be found happily and freely scurrying next to galline talons (rooster chicks) in a kind-of “barnyard symbiosis.”  Their complementary foraging styles reduce pests, and their balanced behavior patterns share warmth and help the skittish chicks relax better. Likewise, RoosterBio can help its customers rest a little easier by substantially reducing the expenditure, with the runway toward an IND brought down to mere months, depending on a program’s needs. [10]

To learn more details of how we can work together and co-pilot your successful CGT program, view the webinar [3], check out our website, or watch a quick video.

 

References

1. RoosterBio. Balancing the Scale from the Cellular Bank. RoosterBio Blog 2025; Available from: https://www.roosterbio.com/blog/balancing-the-scale-from-the-cellular-bank/.
2. RoosterBio. Cell Bank & Scale Up Strategies for MSC & Exosome Manufacturing. RoosterBio 2025; Available from: https://share.hsforms.com/1SWBPWZmMRpy6oclC4bzziw3564o.
3. RoosterBio. Cell Bank And Scale Up Strategies For MSC And Exosome Manufacturing. 2025; Available from: https://www.cellandgene.com/doc/cell-bank-scale-up-strategies-for-msc-exosome-manufacturing-0001.
4. Williams, Kathy & Hansen, Caitlin. Quality Begins at Inception. 2020; Available from: https://www.roosterbio.com/blog/quality-begins-at-inception/.
5. Hildreth, Cade. RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies. 2022; Available from: https://bioinformant.com/roosterbio-and-agc-biologics/.
6. DeVido, Daniel. Fast-Tracking Development of MSC-Based Cell and Extracellular Vesicle Therapies Through a Strategic Partnership. 2022; Available from: https://fujifilmbiotechnologies.fujifilm.com/knowledge-center/resource-library/fast-tracking-development-of-msc-based-cell-and-extracellular-vesicle-therapies-through-a-strategic-partnership/.
7. Nikon CeLL and RoosterBio Ink Licensing Deal to Advance Stem Cell and EV Therapies in Japan. 2025; Available from: https://www.biopharmaboardroom.com/news/44/3211/nikon-cell-and-roosterbio-ink-licensing-deal-to-advance-stem-cell-and-ev-therapies-in-japan.html .
8. RoosterBio. RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing. 2025; Available from: https://www.prnewswire.com/news-releases/roosterbio-announces-collaboration-with-thermo-fisher-scientific-to-advance-cell-and-exosome-therapy-manufacturing-302443376.html.
9. Diamond, Julie. Bridging the Chasm Between Ideation & Commercialization for Advanced Therapy Startups: How to Build Support in the Early Days of Entrepreneurship. 2023; Available from: https://www.roosterbio.com/blog/bridging-the-chasm-between-ideation-commercialization-for-advanced-therapy-startups-how-to-build-support-in-the-early-days-of-entrepreneurship/.
10. RoosterBio. Rapid Translation of a Cellular Therapeutic: Choosing Product & Process Development Solutions for Clinical Manufacturing Readiness. 2022; Available from: https://share.hsforms.com/1YmYCcqpoQLK_tn5AfWNzYQ3564o.